Search: WFRF:(Carnesecchi Stephanie) >
Rimeporide as a fir...
Rimeporide as a first- in-class NHE-1 inhibitor : Results of a phase Ib trial in young patients with Duchenne Muscular Dystrophy
-
- Previtali, Stefano C. (author)
- IRCCS, Dept Neurol, San Raffaele Sci Inst, Milan, Italy.;IRCCS, INSPE, San Raffaele Sci Inst, Milan, Italy.
-
- Gidaro, Teresa (author)
- Hop Trousseau, I Motion, Inst Myol, Paris, France.
-
- Diaz-Manera, Jordi (author)
- Hosp Santa Creu i St Pau Barcelona Serv Neurol, Barcelona, Spain.;Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain.
-
show more...
-
- Zambon, Alberto (author)
- IRCCS, Dept Neurol, San Raffaele Sci Inst, Milan, Italy.;IRCCS, INSPE, San Raffaele Sci Inst, Milan, Italy.
-
- Carnesecchi, Stephanie (author)
- Geneva Univ UNIGE, Geneva, Switzerland.
-
- Roux-Lombard, Pascale (author)
- Geneva Univ Hosp HUG, Immunol & Allergol Dept, Geneva, Switzerland.
-
- Spitali, Pietro (author)
- Leiden Univ, Med Ctr, Leiden, Netherlands.
-
- Signorelli, Mirko (author)
- Leiden Univ, Med Ctr, Leiden, Netherlands.
-
- Al-Khalili Szigyarto, Cristina (author)
- KTH,Systembiologi
-
- Johansson, Camilla (author)
- KTH,Systembiologi
-
- Gray, Julian (author)
- EspeRare, Campus Biotech,Innovat Pk,15 Ave Secheron, CH-1202 Geneva, Switzerland.
-
- Labolle, Delphine (author)
- EspeRare, Campus Biotech,Innovat Pk,15 Ave Secheron, CH-1202 Geneva, Switzerland.
-
- Thome, Florence Porte (author)
- EspeRare, Campus Biotech,Innovat Pk,15 Ave Secheron, CH-1202 Geneva, Switzerland.
-
- Pitchforth, Jacqueline (author)
- UCL Great Ormond St Inst Child Hlth, London, England.;Great Ormond St Hosp Sick Children, Dubowitz Neuromuscular Ctr, London, England.
-
- Domingos, Joana (author)
- UCL Great Ormond St Inst Child Hlth, London, England.;Great Ormond St Hosp Sick Children, Dubowitz Neuromuscular Ctr, London, England.
-
- Muntoni, Francesco (author)
- UCL Great Ormond St Inst Child Hlth, London, England.;Great Ormond St Hosp Sick Children, Dubowitz Neuromuscular Ctr, London, England.;UCL, NIHR Great Ormond St Hosp, Biomed Res Ctr, Ormond St Inst Child Hlth,Great Ormond St Hosp Tr, London, England.
-
show less...
-
IRCCS, Dept Neurol, San Raffaele Sci Inst, Milan, Italy;IRCCS, INSPE, San Raffaele Sci Inst, Milan, Italy. Hop Trousseau, I Motion, Inst Myol, Paris, France. (creator_code:org_t)
- Elsevier BV, 2020
- 2020
- English.
-
In: Pharmacological Research. - : Elsevier BV. - 1043-6618 .- 1096-1186. ; 159
- Related links:
-
https://doi.org/10.1...
-
show more...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Rimeporide, a first-in-class sodium/proton exchanger Type 1 inhibitor (NHE-1 inhibitor) is repositioned by EspeRare for patients with Duchenne Muscular Dystrophy (DMD). Historically, NHE-1 inhibitors were developed for cardiac therapeutic interventions. There is considerable overlap in the pathophysiological mechanisms in Congestive Heart Failure (CHF) and in cardiomyopathy in DMD, therefore NHE-1 inhibition could be a promising pharmacological approach to the cardiac dysfunctions observed in DMD. Extensive preclinical data was collected in various animal models including dystrophin-deficient (mdx) mice to characterise Rimeporide's anti-fibrotic and anti-inflammatory properties and there is evidence that NHE-1 inhibitors could play a significant role in modifying DMD cardiac and also skeletal pathologies, as the NHE-1 isoform is ubiquitous. We report here the first study with Rimeporide in DMD patients. This 4-week treatment, open label phase Ib, multiple oral ascending dose study, enrolled 20 ambulant boys with DMD (6-11 years), with outcomes including safety, pharmacokinetic (PK) and pharmacodynamic (PD) biomarkers. Rimeporide was safe and well-tolerated at all doses. PK evaluations showed that Rimeporide was well absorbed orally reaching pharmacological concentrations from the lowest dose, with exposure increasing linearly with dose and with no evidence of accumulation upon repeated dosing. Exploratory PD biomarkers showed positive effect upon a 4-week treatment, supporting its therapeutic potential in patients with DMD, primarily as a cardioprotective treatment, and provide rationale for further efficacy studies.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Farmaceutiska vetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Pharmaceutical Sciences (hsv//eng)
Keyword
- Duchenne Muscular Dystrophy
- NHE-1
- Rimeporide
- Safety
- Pharmacokinetic
- Cardiomyopathy
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Previtali, Stefa ...
-
Gidaro, Teresa
-
Diaz-Manera, Jor ...
-
Zambon, Alberto
-
Carnesecchi, Ste ...
-
Roux-Lombard, Pa ...
-
show more...
-
Spitali, Pietro
-
Signorelli, Mirk ...
-
Al-Khalili Szigy ...
-
Johansson, Camil ...
-
Gray, Julian
-
Labolle, Delphin ...
-
Thome, Florence ...
-
Pitchforth, Jacq ...
-
Domingos, Joana
-
Muntoni, Frances ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Basic Medicine
-
and Pharmaceutical S ...
- Articles in the publication
-
Pharmacological ...
- By the university
-
Royal Institute of Technology